Models
Model definition
Definitions for Rel, the time course, overlap, and the three kinetic engines. The slider below shifts the evaluation time. Doses that have left the acute window are not plotted; they remain in the journal.
Drag to pan · +/− zoom time · Y = Rel
At this instant
- No acute doses at this evaluation time.
Tone at t
No active synaptic push. Log a compound and the systems map fills in.
Rel
Rel = modeled amount at time t, divided by the peak amount of a typical adult dose of the same compound on the same route. A typical dose peaks at 1.00. Two typical doses of the same compound add; Rel can exceed 1.00.
Rel is not a shared intensity scale. 1.00 caffeine is not 1.00 LSD. Milligram amounts are not comparable across compounds.
Felt intensity
Felt = Hill(Rel) = Reln / (EC50n + Reln) with n ≈ 1.35 and EC50 ≈ 0.55. A typical dose (Rel = 1.00) maps to felt ≈ 0.70. Doubling the dose does not double felt intensity. 1.00 on the felt axis is the model ceiling (Emax), not a typical session. Same compound, multiple doses: Hill of summed Rel (not the sum of Hills). Felt is still not comparable across compounds.
Time course
X is hours relative to now. Y is Rel. The dashed line is Rel = 1.00.
If plasma half-life and labeled duration agree (ratio 0.6–1.5), the curve is first-order absorption and elimination (Bateman function); elimination uses t½. Caffeine, modafinil, and diphenhydramine use this. Rel remains substantial after the labeled session because the drug is still present.
If they disagree, the plotted curve is the acute session: peak at labeled Tmax, Rel ≈ 0.10 at labeled duration. Used when terminal t½ is redistribution (THC) or when receptor occupancy outlasts plasma (LSD, alprazolam, phenibut). Terminal t½ is noted on the compound page and is not the plotted decay.
Overlap
Same compound and route: Rel is summed on one series. Different compounds share the time axis; each Y is Rel versus that compound’s own typical peak.
If the largest peak in the window is more than 2.5× the smallest, each series is scaled to its own peak so small traces remain visible. In that mode Y is not a shared Rel scale; use the Rel value on the card.
Kinetic classes
Default: first-order absorption and elimination. Ethanol: zero-order elimination (Widmark; ~7 g/h scaled by body weight and sex). Chronic entries (creatine, ashwagandha, sertraline, vitamin D): occupancy plateau through labeled duration, then terminal decay — not an acute peak.
Phases
pre-onset, onset, come-up, peak, plateau, offset, afterglow, cleared. Afterglow can remain on the board after the acute trace is below plotting threshold. Cleared: Rel and phase no longer warrant display on Now.
Limits
Parameters are literature-typical adult values. The model does not include CYP genotype, food, gastric emptying, tolerance, receptor downregulation, or verification of the substance taken. It is not a plasma measurement.
Equations
Bateman: C(t) ∝ F·Dose·ka/(ka−ke)·(e−ke t − e−ka t), ke = ln2 / t½ when t½ and duration agree. Session-shaped curves: rise to Tmax, then exponential decay with ke = ln(10)/(duration − Tmax). Synaptic map: Hill(Rel; n ≈ 1.35, EC50 ≈ 0.55 of typical peak). Stacked tone: 1 − Π(1 − |w·e|), signed. Sources: each library entry and the Sources page.
Ubermensch models typical adult pharmacokinetics and receptor action. It is not a measurement of your plasma, and it does not diagnose, treat, or replace a clinician. Parameters are literature-typical and will not match every individual.